Massachusetts General Hospital Completes Study & Concludes Tocilizumab Not Helpful for Hospitalized COVID-19 Patients

TrialSite has reported on a few different study results indicating that Roche’s Actemra (tocilizumab), an IL-6 inhibitor, doesn’t help to lower the death rate for hospitalized patients infected with severe to critical COVID-19. Now study results, recently published in...

Genentech (Roche) Collaborates with BARDA to Launch Actemra Clinical Trial for Adult Patients with Severe COVID-19 Pneumonia

Genentech (Roche) plans a Phase III clinical trial to assess its marketed drug Actemra (tocilizumab) as a treatment for severe cases of COVID-19 in adults. In collaboration with the Biomedical Advanced Research and Development Authority (BARDA), the prominent company...

Pin It on Pinterest